Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age.
childhood cancer
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
rhabdomyosarcoma
sarcomatosis
toxicity
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
09
07
2018
revised:
19
09
2018
accepted:
02
10
2018
pubmed:
27
10
2018
medline:
7
11
2019
entrez:
27
10
2018
Statut:
ppublish
Résumé
Advanced and relapsed intraperitoneal rhabdomyosarcomas in young children represent an oncological challenge and options for local tumor control are limited. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is commonly used in advanced peritoneal tumors in adults. However, no studies are available regarding CRS and HIPEC in young children. We report our experiences treating six patients with intraperitoneal rhabdomyosarcoma with CRS and HIPEC using cisplatin and doxorubicin focusing on safety and outcomes. No procedure-associated mortalities occurred and no major short- or long-term toxicities were recorded. All patients showed no evidence of disease after 12-month median (7-41) follow-up.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27517Informations de copyright
© 2018 Wiley Periodicals, Inc.